Facebook
Twitter
LinkedIn
ForwardThrough its educational arm, the ISTH Academy, the International Society on Thrombosis and Haemostasis (ISTH) has begun hosting a series of webinars on practical thrombosis and haemostasis issues that scientists and physicians frequently confront. These webinars will allot time for participants to ask questions and will cover the latest information on relevant topics.
Biological Mechanisms Involved in Cancer Coagulopathy – Janusz Rak
The presentation will review some of the biological mechanisms linking thrombosis to cancer progression, including the role of tumour-associated vascular anomalies, systemic nature of the advanced disease and the impact of oncogenic mutations on the coagulant phenotype of cancer cells. Experimental evidence will also be considered in relation to the possible involvement of the coagulation system effectors, especially tissue factor, in the biology cancer cells, including events surrounding tumour initiation, angiogenic switch, inflammatory responses and their therapeutic implications.
Prevention and Treatment – Alok Khorana
Overview of approaches to prevention including identifying patients at high risk for venous thromboembolism. The talk will also cover and best practices in treatment of cancer-associated thrombosis
Accreditation Statement
Sponsored by an unrestricted educational grant from Instrumentation Laboratory
Clinicians and trainees who are interested in the biological mechanisms linking cancer and thrombosis and how to prevent and treat thrombosis in cancer patients. Researchers and non-medical trainees with an interest in the vascular abnormalities in cancer would also be interested in the presentation.
At the conclusion of this activity, I will be able to:
- To consider the convergence of vascular, blood-related and tumour-related events underlying thrombosis in cancer patients.
- To appreciate the complexity and disease-specific aspects amongst processes occurring at the tumour-vascular interface which contribute to coagulation system activation in cancer.
- To discuss the possible impact of coagulation system activation on the biology of cancer cells.
- To understand the link between oncogenic driver events and their related changes in the molecular repertoire of coagulant effector genes (coagulome) in specific cancer subtypes.
- To highlight coagulopathy as a systemic manifestation of the malignant process and a step in the continuum of coordinated biological responses, including inflammation, angiogenesis and tissue repair programs.
- Understand risk assessment for cancer-associated thrombosis
- Identify appropriate strategies for thromboprophylaxis
- Outline best treatments of cancer-associated thrombosis
Alok A. Khorana, MD
Janusz Rak, MD, PhD
Moderator, Chris WardName | Company | Role |
Chris Ward, MD | Bayer | Advisory Board, Speaker |
| Pfizer, BMS | Advisory Board, Speaker |
| Boehringer-Ingelheim | Advisory Board, Speaker |
| Alexion | Advisory Board |
| Medimark | Steering Committee Member, Speaker |
Geoff Barnes | BMS, Pfizer, Blue Cross Blue Shield of Michigan | Primary Investigator & Co-Investigator |
Yukio Ozaki | Sysmex | Advisory Board |
| Janusz Rak | NX PharmaGen | Intellectual Property |
| Alok Khorana | Leo | Steering Committee |
| Janssen | Steering Committee | |
| Pfizer | Consulting |
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.